# Atsushi Usami

> Atsushi Usami is a Series B investor at UTEC - The University of Tokyo Edge Capital Partners backing Health Care. See 13 investments, check sizes, portfolio…

- Type: Angel Investor
- Fund: [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec)
- Location: Tokyo, Japan
- Total investments: 13
- Last investment: Oct 2025
- Lead investor: 62%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/atsushi-usami-77b24398
- Website: https://x.com/AtsushiUsami_VC
- Facebook: https://www.facebook.com/atsushi.usami.56

Atsushi Usami is a Series B investor at UTEC - The University of Tokyo Edge Capital Partners in Tokyo focused on Health Care and Biotechnology. Atsushi Usami is based out of Tokyo, Tokyo and is the Board Members of Pahr Therapeutics. Atsushi Usami attended The University of Tokyo.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 38% |
| Biotechnology | 5 | 38% |
| Medical | 4 | 31% |
| Life Science | 3 | 23% |
| Therapeutics | 2 | 15% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 38% |
| Seed | 4 | 31% |
| Pre-Seed | 1 | 8% |
| Series A | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 5 | 38% |
| India | 1 | 8% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Celaid Therapeutics | Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M | Series B | Oct 07, 2025 |  |
| Pahr Therapeutics | Pahr Therapeutics is a clinical-stage business whose goal is to create innovative ways to treat pulmonary arterial hypertension. | $14M | Seed | Jul 28, 2025 |  |
| RegCell | RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer . | $8.5M | Seed | Mar 18, 2025 |  |
| Celaid Therapeutics | Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M | Series A | May 08, 2024 |  |
| Violet Therapeutics | Violet Therapeutics is a healthcare company that operates in stealth mode. | $10.6M | Seed | May 05, 2023 |  |
| OriCiro Genomics | OriCiro Genomics creates a better bioeconomy with innovative genome technologies. The company is a pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology.The company creates a technology that covers "DNA assembly" and "circular DNA amplification", allowing to construct large circularDNA molecules without relying on conventional biological cloning. |  | Series B | Jun 05, 2022 |  |
| BUGWORKS Research | BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $18M | Series B | Feb 09, 2022 |  |
| OriCiro Genomics | OriCiro Genomics creates a better bioeconomy with innovative genome technologies. The company is a pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology.The company creates a technology that covers "DNA assembly" and "circular DNA amplification", allowing to construct large circularDNA molecules without relying on conventional biological cloning. | $7.3M | Series B | Jul 20, 2021 |  |
| Metcela | Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies.Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan. | $12.7M | Series B | Jan 04, 2021 |  |
| BitBiome | BitBiome is a biotechnology company focused on analyzing microbial genomes and discovering enzymes and proteins that can be applied across industries such as pharmaceuticals, food production, and sustainable manufacturing. The company uses single-cell microbial sequencing technology to study microbes that are difficult to culture throughconventional laboratory methods, enabling the creation of a large microbial genome database called bit-GEM. Its platform supports enzyme discovery, genome analysis, and bioengineering efforts aimed at developing bio-based alternatives for industrial processes. bitBiome also works with academic institutions and commercial partners on research projects involving areas such as biodegradable materials, biomass conversion, and pharmaceutical ingredient synthesis. The company positions microbes as a resource for advancing the bioeconomy by providing tools and data that support biotechnology research and industrial applications. | $6.6M | Series B | Sep 01, 2020 |  |

10 of 13 investments shown.

## Co-investors
- [Osaka University Venture Capital](https://shizune.co/investors/profile/osaka-university-venture-capital) — VC Fund, 3 deals together
- [Acquipharma](https://shizune.co/investors/profile/acquipharma) — VC Fund, 2 deals together
- [Global Brain Corporation](https://shizune.co/investors/profile/global-brain-corporation) — VC Fund, 2 deals together
- [ITOCHU Technology Ventures](https://shizune.co/investors/profile/itochu-technology-ventures) — VC Fund, 2 deals together
- [Joyo Capital Partners](https://shizune.co/investors/profile/joyo-capital-partners) — VC Fund, 2 deals together
- [Techno Science](https://shizune.co/investors/profile/techno-science) — VC Fund, 2 deals together

## About UTEC - The University of Tokyo Edge Capital Partners

VC Fund · Tokyo, Japan

UTEC - The University of Tokyo Edge Capital Partners, is a Japan-based seed/early stage deep-tech venture capital firm associated with academic institutes such as The University of Tokyo. UTEC has over $1 billion in Assets Under Management, and has invested in 150+ companies in Japan, USA, Singapore, India and Europe with a track record of 20IPOs and 22 successful M&A (as of Nov 2025). UTEC predominantly invests in three deep-tech sectors: a) Healthcare & Life Sciences, b) IT/AI, and c) Physical Sciences & Engineering.

5 contacts available at UTEC - The University of Tokyo Edge Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Atsushi Usami | Partner & Board Director | https://shizune.co/investors/profile/atsushi-usami |
| Hiroaki Kobayashi | Principal | https://shizune.co/investors/profile/hiroaki-kobayashi-3588 |
| Keisuke Ide | Partner | https://shizune.co/investors/profile/keisuke-ide |
| Kiran Mysore | Principal | https://shizune.co/investors/profile/kiran-mysore |
| Maiko Katadae | Partner | https://shizune.co/investors/profile/maiko-katadae |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Atsushi Usami invest in?

Atsushi Usami invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 13 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Atsushi Usami last invest?

The most recent investment recorded for Atsushi Usami closed in Oct 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co